Research programme: epigenetic chronic obstructive pulmonary disease therapeutics - BioMed X/Boehringer Ingelheim
Latest Information Update: 07 Jan 2015
At a glance
- Originator BioMed X; Boehringer Ingelheim
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Chronic obstructive pulmonary disease
Most Recent Events
- 05 Jan 2015 Early research in Chronic obstructive pulmonary disease in Germany (unspecified route)